Published in Proc Natl Acad Sci U S A on February 01, 1993
Epidermal growth factor system regulates mucin production in airways. Proc Natl Acad Sci U S A (1999) 2.57
Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol (1997) 2.05
Apoptosis: targets in pancreatic cancer. Mol Cancer (2003) 1.31
The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology (2008) 1.29
Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression. Mol Cancer (2011) 1.16
Interleukin 1 alpha and tumor necrosis factor alpha stimulate autocrine amphiregulin expression and proliferation of human papillomavirus-immortalized and carcinoma-derived cervical epithelial cells. Proc Natl Acad Sci U S A (1995) 1.14
Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respir Res (2007) 1.13
TNF-α induces upregulation of EGFR expression and signaling in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol (2012) 1.03
Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. Proc Natl Acad Sci U S A (1993) 1.01
Aging and inflammation: etiological culprits of cancer. Curr Aging Sci (2009) 0.97
MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder. Am J Pathol (2006) 0.91
Tumor necrosis factor-alpha impairs intestinal phosphate absorption in colitis. Am J Physiol Gastrointest Liver Physiol (2009) 0.90
Analysis of the cytochrome c-dependent apoptosis apparatus in cells from human pancreatic carcinoma. Br J Cancer (2002) 0.87
Expression of pro-inflammatory TACE-TNF-α-amphiregulin axis in Sjögren's syndrome salivary glands. Histochem Cell Biol (2010) 0.84
Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway. Br J Cancer (1994) 0.84
To NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate Regulator. Transl Med UniSa (2012) 0.82
Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc Natl Acad Sci U S A (1997) 0.80
Phosphatidic Acid (PA) can Displace PPARα/LXRα Binding to The EGFR Promoter Causing its Transrepression in Luminal Cancer Cells. Sci Rep (2015) 0.78
TNF-α increases endothelial progenitor cell adhesion to the endothelium by increasing bond expression and affinity. Am J Physiol Heart Circ Physiol (2014) 0.78
BCG response prediction with cytokine gene variants and bladder cancer: where we are? J Cancer Res Clin Oncol (2011) 0.77
The diverse roles of the TNF axis in cancer progression and metastasis. Trends Cancer Res (2016) 0.77
Tumor necrosis factor-alpha promoter polymorphism 308 G/A is not significantly associated with esophageal cancer risk: a meta-analysis. Oncotarget (2016) 0.77
17β-Estradiol Inhibites Tumor Necrosis Factor-α Induced Apoptosis of Human Nucleus Pulposus Cells via the PI3K/Akt Pathway. Med Sci Monit (2016) 0.75
Gene Variants in Predicting BCG Response to Urinary Bladder Cancer. Indian J Clin Biochem (2012) 0.75
Tumor suppressor SET9 guides the epigenetic plasticity of breast cancer cells and serves as an early-stage biomarker for predicting metastasis. Oncogene (2016) 0.75
Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature (1984) 24.45
Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 22.72
Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res (1987) 4.44
Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. J Biol Chem (1991) 3.06
Transforming growth factor-beta controls receptor levels for epidermal growth factor in NRK fibroblasts. Cell (1984) 2.30
LIGAND: a computerized analysis of ligand binding data. Methods Enzymol (1983) 1.84
Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol (1991) 1.58
Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J Biol Chem (1984) 1.55
Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci U S A (1987) 1.51
Altered epidermal growth factor (EGF)-stimulated protein kinase activity in variant A431 cells with altered growth responses to EGF. Proc Natl Acad Sci U S A (1982) 1.47
The epidermal growth factor receptor in human pancreatic cancer. J Pathol (1992) 1.47
Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells. Biochem J (1988) 1.42
Epidermal growth factor regulates the expression of its own receptor. Proc Natl Acad Sci U S A (1985) 1.41
Tumor necrosis factor signal transduction. Cell-type-specific activation and translocation of protein kinase C. J Immunol (1990) 1.39
IL-1 and TNF transmodulate epidermal growth factor receptors by a protein kinase C-independent mechanism. J Immunol (1989) 1.33
Regulation of epidermal growth factor receptor by estrogen. J Biol Chem (1985) 1.32
Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys (1987) 1.29
Epidermal growth factor (EGF) stimulates EGF receptor synthesis. J Biol Chem (1986) 1.24
Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res (1987) 1.13
Transforming growth factor-alpha: an oncodevelopmental growth factor. Cancer Cells (1990) 1.12
Epidermal growth factor stimulates the synthesis of its own receptor in a human breast cancer cell line. J Biol Chem (1986) 1.12
Tumor necrosis factor alpha is an autocrine growth regulator during macrophage differentiation. Proc Natl Acad Sci U S A (1992) 1.11
Tumor necrosis factor increases the number of epidermal growth factor receptors on human fibroblasts. J Biol Chem (1987) 1.04
Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity. J Biol Chem (1989) 0.97
Antiproliferative effects exerted by recombinant human tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) on human pancreatic tumor cell lines. Pancreas (1988) 0.93
Modulation of platelet-derived growth factor A- and B-chain/c-sis mRNA by tumor necrosis factor and other agents in adenocarcinoma cells. Oncogene (1991) 0.92
Transforming growth factor-alpha. Mol Reprod Dev (1990) 0.91
The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol (1990) 0.91
Monoclonal antibody-defined human pancreatic cancer-associated antigens. Cancer Res (1985) 0.90
Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. Cancer Res (1991) 0.86
Modulation of transforming growth factor alpha-dependent expression of epidermal growth factor receptor gene by transforming growth factor beta, triiodothyronine, and retinoic acid. J Cell Biochem (1989) 0.84
Regulation of the epidermal growth factor receptor by growth-modulating agents: effects of staurosporine, a protein kinase inhibitor. Cancer Res (1990) 0.83
Association of interferon-gamma induced growth inhibition and modulation of epidermal growth factor receptor gene expression in squamous cell carcinoma cell lines. J Biol Regul Homeost Agents (1989) 0.83
Phosphatidylcholine metabolism in endothelial cells: evidence for phospholipase A and a novel Ca2+-independent phospholipase C. Biochim Biophys Acta (1987) 0.83
Structural and functional analysis of the rat testis-specific histone H1t gene. J Cell Biochem (1990) 0.79
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch (2001) 2.73
Mathematical modeling reveals threshold mechanism in CD95-induced apoptosis. J Cell Biol (2004) 2.70
Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene (2006) 2.36
Zebrafish: an emerging model system for human disease and drug discovery. Clin Pharmacol Ther (2007) 1.89
Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol (1994) 1.78
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis. Oncogene (2000) 1.69
Mechanism for elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function of Bin1 in melanoma. Proc Natl Acad Sci U S A (1999) 1.68
Risk factors for early dislocation after total hip arthroplasty: a matched case-control study. J Orthop Surg (Hong Kong) (2010) 1.68
The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol (2000) 1.67
p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene (1993) 1.62
Biology of tumor progression in human melanocytes. Lab Invest (1987) 1.61
Immunochemical characterization and quantitative distribution of pancreatic stone protein in sera and pancreatic secretions in pancreatic disorders. Gastroenterology (1990) 1.60
Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res (1996) 1.59
Reaction of lectins with human erythrocytes. III. Surface charge density and agglutination. Exp Cell Res (1976) 1.57
DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene (2000) 1.56
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene (2006) 1.55
Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci U S A (1986) 1.54
Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell (2001) 1.52
Regulation of NK cell functions by TGF-beta 1. J Immunol (1995) 1.51
Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol (1999) 1.47
Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene (2001) 1.46
Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res (2001) 1.44
Chromatin binding of epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells bearing the appropriate surface receptors. Proc Natl Acad Sci U S A (1986) 1.44
Immunocytological detection of micrometastatic cells: comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients. Int J Cancer (1994) 1.39
Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR. Cancer Res (1997) 1.36
Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia (1995) 1.35
Molecular cloning of cDNA for the human tumor-associated antigen CO-029 and identification of related transmembrane antigens. Proc Natl Acad Sci U S A (1990) 1.35
Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene (2009) 1.32
Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scand J Immunol (2007) 1.32
Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys (1987) 1.29
Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res (1998) 1.28
Immunohistochemical screening for beta6-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong up-regulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology (2004) 1.28
Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer (2003) 1.24
Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro. Adv Cancer Res (1990) 1.23
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst (1989) 1.23
Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J Biol Chem (2000) 1.21
The detection of disseminated tumor cells in bone marrow from colorectal-cancer patients by a cytokeratin-20-specific nested reverse-transcriptase-polymerase-chain reaction is related to the stage of disease. Int J Cancer (1996) 1.21
Lovastatin inhibits proliferation of pancreatic cancer cell lines with mutant as well as with wild-type K-ras oncogene but has different effects on protein phosphorylation and induction of apoptosis. Int J Oncol (1998) 1.18
Identification of prognostic factors for chronicity in patients with low back pain: a review of screening instruments. Int Orthop (2009) 1.17
Condition-specific outcome measures for low back pain. Part I: validation. Eur Spine J (2004) 1.17
Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol (1996) 1.14
Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas. Cancer Res (1987) 1.13
DPC4/SMAD4 mediated tumor suppression of colon carcinoma cells is associated with reduced urokinase expression. Oncogene (1999) 1.13
Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res (1987) 1.13
ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer (2004) 1.11
CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene (2001) 1.10
FAP-1 in pancreatic cancer cells: functional and mechanistic studies on its inhibitory role in CD95-mediated apoptosis. J Cell Sci (2001) 1.10
Expression of melanoma-associated antigens in rapidly dividing human melanocytes in culture. Cancer Res (1987) 1.09
Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1. J Cell Physiol (1997) 1.08
TLR-3 polymorphism is an independent prognostic marker for stage II colorectal cancer. Eur J Cancer (2011) 1.07
Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res (1989) 1.07
Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. Gastroenterology (1996) 1.05
Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker. Ann Surg (1998) 1.04
Aberrant activation of c-kit protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res (2001) 1.01
Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. Proc Natl Acad Sci U S A (1993) 1.01
Differential expression and subcellular distribution of the mouse metastasis-associated proteins Mta1 and Mta3. Gene (2001) 1.01
In vivo studies on the incorporation of microinjected acidic proteins of the large ribosomal subunit from Escherichia coli and artermia salina into oocyte ribosomes from Xenopus laevis. Biochemistry (1979) 1.00
Matrix-independent survival of human keratinocytes through an EGF receptor/MAPK-kinase-dependent pathway. Mol Biol Cell (2001) 1.00
Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res (2001) 1.00
Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Cancer Res Clin Oncol (1999) 1.00
Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol (1995) 0.99
Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Oncogene (2007) 0.99
Monoclonal antibody defines CA 19-9 in pancreatic juices and sera. Gut (1985) 0.98
Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products. Cancer Res (1986) 0.96
Disseminated tumour cells. Their detection and significance for prognosis of gastrointestinal and pancreatic carcinomas. Virchows Arch (2001) 0.96
Differential expression of transforming growth factors-beta1, -beta2 and -beta3 in human colon carcinoma. Eur J Cancer (2001) 0.96
Autocrine stimulation of human pancreatic duct-like development by soluble isoforms of epimorphin in vitro. J Cell Biol (2001) 0.96
Cytokine-induced expression of transforming growth factor-alpha and the epidermal growth factor receptor in neonatal skin explants. J Invest Dermatol (1992) 0.95
Development of invasive and growth factor-independent cell variants from primary human melanomas. Cancer Res (1991) 0.95
Bovine serum albumin reverses inhibition of RT-PCR by melanin. Biotechniques (1998) 0.95
Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation. Cell Death Differ (2010) 0.95
Autoantibodies in sera of pancreatic cancer patients identify recombination factor Rad51 as a tumour-associated antigen. J Cancer Res Clin Oncol (2002) 0.94
A central role of Bcl-X(L) in the regulation of keratinocyte survival by autocrine EGFR ligands. J Invest Dermatol (1999) 0.93
Antiproliferative effects exerted by recombinant human tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma) on human pancreatic tumor cell lines. Pancreas (1988) 0.93
Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. Br J Cancer (2006) 0.93
Disseminated tumor cells in pancreatic cancer patients detected by immunocytology: a new prognostic factor. Clin Cancer Res (1999) 0.93
Orthotopic transplantation model of human gastrointestinal cancer and detection of micrometastases. World J Gastroenterol (2001) 0.92
Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model. Ann Thorac Surg (2001) 0.92
Modulation of platelet-derived growth factor A- and B-chain/c-sis mRNA by tumor necrosis factor and other agents in adenocarcinoma cells. Oncogene (1991) 0.92
A tumor-selective somatostatin analog (TT-232) with strong in vitro and in vivo antitumor activity. Proc Natl Acad Sci U S A (1996) 0.91
Epidermal growth factor (EGF) and monoclonal antibody to cell surface EGF receptor bind to the same chromatin receptor. Arch Biochem Biophys (1989) 0.91
Overexpression of p53 protein during pancreatitis. Br J Cancer (1997) 0.91
Monoclonal antibody-defined human pancreatic cancer-associated antigens. Cancer Res (1985) 0.90
Condition-specific outcome measures for low back pain. Part II: scale construction. Eur Spine J (2004) 0.90
Expression and transcriptional regulation of caspase-14 in simple and complex epithelia. Cell Death Differ (2002) 0.90
An episomal vector for stable tetracycline-regulated gene expression. Nucleic Acids Res (1997) 0.89
Intact tissue of gastrointestinal cancer specimen orthotopically transplanted into nude mice. Hepatogastroenterology (1999) 0.88
WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J Pathol (1997) 0.88
Immunotargeting and eradication of orthotopic melanoma using a chemokine-enhanced DNA vaccine. Gene Ther (2013) 0.88
Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer (2001) 0.88
Ribosomal protein S6 from Xenopus laevis ovaries. Isolation, phosphorylation in vivo and cross-reaction with heterologous anti-S6 antibodies. Eur J Biochem (1982) 0.88
The TNF family member APRIL promotes colorectal tumorigenesis. Cell Death Differ (2012) 0.88